Cancer

Imugene to demonstrate the benefits of combination tumor treatment

Finfeed Archived Oct 21, 2019

Imugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology.

GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer

Next Investors Archived Oct 02, 2019

Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).

Genetic Technologies surges 40% on back of agreement

Finfeed Archived Sep 23, 2019

Provider of world-leading genetic risk assessment test products Genetic Technologies Limited (ASX:GTG), has signed a 3-year Collaboration Agreement with TGen.

Rhythm’s lead biomarker successfully differentiates between cancer and healthy samples

Finfeed Archived Sep 19, 2019

New antibodies for the key lead biomarker used in Rhythm Biosciences' (ASX: RHY) ColoSTAT® test can successfully differentiate between cancer and healthy samples, and the test has now been optimised.

A healthy six pack in a hot sector: Part 2

Finfeed Archived Sep 11, 2019

The S&P/ASX 200 Healthcare Sector blitzed the rest of the market, increasing 12.7% against the ASX 200 which interestingly by the start of September was already back in positive territory, up 4.5%.

A healthy six pack in a hot sector: Part 1

Finfeed Archived Sep 10, 2019

Finfeed has come up with six stocks in the healthcare and bioscience sectors that appear to have plenty going for them in fiscal 2020.

Imagion shares up 12% on the back of today's Magsense news

Finfeed Archived Sep 09, 2019

Imagion’s shares received a boost with strong trading throughout the morning resulting in an increase from the previous day’s close of 4.1 cents to 4.5 cents just before midday.

Imagion MRI applications as a new source of revenue

Finfeed Archived Sep 09, 2019

Imagion Biosystems (ASX:IBX) advised the market of early-stage evidence that the technology could have applications in improving magnetic resonance imaging (MRIs).

Podcast: How Imagion is bringing cancer diagnostics into the 21st century

Finfeed Archived Aug 28, 2019

Imagion Biosystems (ASX:IBX) CEO, Robert Proulx speaks to Finfeed's Jonathan Jackson about the company's important work in early stage cancer detection.

< prev Page 3 of 7 next >